CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to LLY

Duloxetine Hydrochloride (HCI)

Phase 3
Eli Lilly and Company (LLY)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

9

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Multiple Sclerosis

Clinical Trial

NCT00755807

Last updated: 11/11/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMAPending

Duloxetine Sandoz

Treatment in adults of major depressive disorder, diabetic peripheral neuropathic pain and generalised anxiety disorder.

View on EMA
EMA8/20/2015

Duloxetine Zentiva

Treatment depressive disorder, diabetic neuropathic pain, anxiety disorder. Duloxetine Zentiva is indicated in adults.

View on EMA
EMA6/19/2015

Duloxetine Viatris (previously Duloxetine Mylan)

Treatment of major depressive disorder Treatment of diabetic peripheral neuropathic pain Treatment of generalised anxiety disorder Duloxetine Viatris is indicated in adults

View on EMA
EMA12/8/2014

Duloxetine Lilly

Duloxetine Lilly is indicated in adults for: Treatment of major depressive disorder Treatment of diabetic peripheral neuropathic pain Treatment of generalised anxiety disorder Duloxetine Lilly is indicated in adults.

View on EMA
EMA10/8/2008

Duloxetine Boehringer Ingelheim

Treatment of diabetic peripheral neuropathic pain in adults.

View on EMA
EMA12/17/2004

Cymbalta

Treatment of major depressive disorder. Treatment of diabetic peripheral neuropathic pain. Treatment of generalised anxiety disorder. Cymbalta is indicated in adults.

View on EMA
EMA12/17/2004

Nodetrip (previously Xeristar)

Treatment of major depressive disorder; Treatment of diabetic peripheral neuropathic pain; Treatment of generalised anxiety disorder; Xeristar is indicated in adults.

View on EMA
EMA8/11/2004

Ariclaim

Treatment of diabetic peripheral neuropathic pain. Ariclaim is indicated in adults.

View on EMA
EMA8/11/2004

Yentreve

Yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (SUI).

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.